Abstract
Mechanisms of prostate cancer recurrence during androgen deprivation are poorly understood. Recently, the putative role of apolipoprotein E ɛ4 allele in the aetiology of prostate cancer was raised. To investigate the hypothesis that ɛ4 allele of apolipoprotein E gene predisposes to prostate cancer and is involved in the relapse of hormonal therapy response, 38 hormone-refractory locally recurrent carcinoma samples from 38 prostate cancer patients were screened for apolipoprotein E genotype. The frequency distribution of apolipoprotein E genotypes among tumours did not differ significantly from that among controls. The allele frequency of ɛ4 was 19.7% and 19.3% in tumours and controls, respectively. The results suggest that clinical progression of prostate cancer during androgen withdrawal therapy is not associated with apolipoprotein E genotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haapala, K., Lehtimäki, T., Ilveskoski, E. et al. Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis 3, 107–109 (2000). https://doi.org/10.1038/sj.pcan.4500405
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500405
Keywords
This article is cited by
-
Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis
Scientific Reports (2015)
-
Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis
Journal of Cancer Research and Clinical Oncology (2014)